Pharmaceutical Technology1 天
Obrixtamig by Boehringer Ingelheim International for Small-Cell Lung Cancer: Likelihood of ...
Obrixtamig is under clinical development by Boehringer Ingelheim International and currently in Phase I for Small-Cell Lung Cancer.
Pharmaceutical Technology1 天
BI-765049 by Boehringer Ingelheim International for Non-Small Cell Lung Cancer: Likelihood ...
BI-765049 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer.